Do Kim
Stock Analyst at Piper Sandler
(2.02)
# 3,047
Out of 5,140 analysts
92
Total ratings
44.93%
Success rate
3.01%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $83.15 | -24.23% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $30.39 | +51.37% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $476.90 | -37.93% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $151.40 | -26.02% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $11.53 | +654.55% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $1.17 | +1,865.81% | 2 | Jan 19, 2023 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $35.46 | -43.60% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $8.64 | +397.69% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $43.63 | -26.66% | 1 | Jul 26, 2022 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $21 → $22 | $3.04 | +623.68% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $48.00 | -60.42% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $5.44 | +194.12% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $336.19 | -44.97% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $3.58 | +25,039.66% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $70.98 | -50.69% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $1.46 | +1,269.86% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $83.15
Upside: -24.23%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $30.39
Upside: +51.37%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $476.90
Upside: -37.93%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $151.40
Upside: -26.02%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $11.53
Upside: +654.55%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $1.17
Upside: +1,865.81%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $35.46
Upside: -43.60%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $8.64
Upside: +397.69%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $43.63
Upside: -26.66%
AbCellera Biologics
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $3.04
Upside: +623.68%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $48.00
Upside: -60.42%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $5.44
Upside: +194.12%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $336.19
Upside: -44.97%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $3.58
Upside: +25,039.66%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $70.98
Upside: -50.69%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $1.46
Upside: +1,269.86%